In mouse models of inflammatory bowel disease, taking inositol hexakisphosphate orally is associated with increased HDAC3 activity, decreased leakage in the intestinal lining, and improved barrier...

We analyzed the available evidence and found that in mouse models of inflammatory bowel disease, oral inositol hexakisphosphate is associated with increased HDAC3 activity, reduced leakage in the intestinal lining, and improved barrier function [1]. This is the only evidence we’ve reviewed so far, and no studies have contradicted this finding. HDAC3 is an enzyme involved in regulating gene activity in gut cells, and its activity may help maintain the integrity of the intestinal barrier — the layer that controls what passes from the gut into the bloodstream. When this barrier becomes too permeable, it can allow unwanted substances to leak through, which may contribute to inflammation. In these mouse studies, taking inositol hexakisphosphate by mouth appeared to support the barrier’s function by boosting HDAC3 and reducing leakage. We note that all the evidence comes from animal models, and no human studies have been reviewed. The dose, timing, and long-term effects in humans are unknown. While the results in mice are consistent and show a clear pattern, we cannot say whether the same changes occur in people with inflammatory bowel disease. What we’ve found so far suggests that inositol hexakisphosphate may have a role in supporting gut barrier health through HDAC3 in mice, but we don’t yet know if this translates to humans. More research is needed to understand whether this effect holds outside of laboratory settings. If you’re considering inositol hexakisphosphate for gut health, talk to a healthcare provider — mouse results don’t always predict human outcomes.